FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield

FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.